(Q37963955)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22136182%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Benefit-risk assessment of bevacizumab in the treatment of breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22136182%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22136182%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Rodrigo Dienstmann

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22136182%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Kamal S Saini

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22136182%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Otto Metzger-Filho

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22136182%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

1 reference

1 January 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22136182%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22136182%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22136182%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22136182%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

15-25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22136182%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/11595910-000000000-00000

17 January 2020

exact match

0 references

cites work

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Avastin's commercial march suffers setback.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595910-000000000-00000

The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors

21 January 2018

1 reference

12 December 2020

Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience

1 reference

12 December 2020

Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes

1 reference

12 December 2020

Bevacizumab and breast cancer: the E2100 outlier

1 reference

12 December 2020

A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners?

1 reference

12 December 2020

RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br

1 reference

12 December 2020

Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions

1 reference

12 December 2020